This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Loprinzi, C. L. Articles by Rummans, T. A. Search for Related Content PubMed PubMed Citation Articles by Loprinzi, C. L. Articles by Rummans, T. A.

Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes

Mayo Clinic and Foundation, Rochester, MN; Mayo Clinic and Foundation, Jacksonville, FL; McAuley Cancer Care Center, Ann Arbor, MI; Creighton Cancer Center, Omaha, NE; and Mayo Clinic and Foundation, Scottsdale, AZ.

Address reprint requests to Charles L. Loprinzi, MD, Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905; email: cloprinzi{at}mayo.edu

PURPOSE: Hot flashes can be a prominent problem in women with a history of breast cancer. Given concerns regarding the use of hormonal therapies in such patients, other nonhormonal means for treating hot flashes are required. Based on anecdotal information regarding the efficacy of fluoxetine and other newer antidepressants for treating hot flashes, the present trial was developed.

PATIENTS AND METHODS: This trial used a double-blinded, randomized, two-period (4 weeks per period), cross-over methodology to study the efficacy of fluoxetine (20 mg/d) for treating hot flashes in women with a history of breast cancer or a concern regarding the use of estrogen (because of breast cancer risk). Eligible patients had to have reported that they averaged at least 14 hot flashes per week; they could have received tamoxifen or raloxifene as long as they were on a stable dose. The major outcome measure was a bivariate construct representing hot flash frequency and hot flash score, analyzed by a classic sums and differences cross-over analysis.

RESULTS: Eighty-one randomized women began protocol therapy. By the end of the first treatment period, hot flash scores (frequency x average severity) decreased 50% in the fluoxetine arm versus 36% in the placebo arm. Cross-over analysis demonstrated a significantly greater marked hot flash score improvement with fluoxetine than placebo (P = .02). The results were not adjusted for potential confounding influences, including age and tamoxifen use. The fluoxetine was well tolerated.

CONCLUSION: This dose of fluoxetine resulted in a modest improvement in hot flashes.

This article has been cited by other articles:

				M. Hickey, C. Saunders, A. Partridge, N. Santoro, H. Joffe, and V. Stearns Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer Ann. Onc., June 16, 2008; (2008) mdn353v2. [Abstract] [Full Text] [PDF]

				Writing Group for the British Menopause Society Co, J. Pitkin, M. C P Rees, S. Gray, M. A. Lumsden, J. Marsden, J. C Stevenson, and J. Williamson Non-estrogen-based treatments for menopausal symptoms Menopause Int, June 1, 2008; 14(2): 88 - 90. [Abstract] [Full Text] [PDF]

				J. W. Goodwin, S. J. Green, C. M. Moinpour, J. D. Bearden III, J. K. Giguere, C. S. Jiang, S. M. Lippman, S. Martino, and K. S. Albain Phase III Randomized Placebo-Controlled Trial of Two Doses of Megestrol Acetate as Treatment for Menopausal Symptoms in Women With Breast Cancer: Southwest Oncology Group Study 9626 J. Clin. Oncol., April 1, 2008; 26(10): 1650 - 1656. [Abstract] [Full Text] [PDF]

				L. Speroff, M. Gass, G. Constantine, S. Olivier, and for the Study 315 Investigators Efficacy and Tolerability of Desvenlafaxine Succinate Treatment for Menopausal Vasomotor Symptoms: A Randomized Controlled Trial Obstet. Gynecol., January 1, 2008; 111(1): 77 - 87. [Abstract] [Full Text] [PDF]

				E. Serrano and J. J. K. Warnock Depressive Disorders Related to Female Reproductive Transitions Journal of Pharmacy Practice, October 1, 2007; 20(5): 385 - 391. [Abstract] [PDF]

				D. Grady, B. Cohen, J. Tice, M. Kristof, A. Olyaie, and G. F. Sawaya Ineffectiveness of Sertraline for Treatment of Menopausal Hot Flushes: A Randomized Controlled Trial Obstet. Gynecol., April 1, 2007; 109(4): 823 - 830. [Abstract] [Full Text] [PDF]

				S Loibl, K Schwedler, G von Minckwitz, R Strohmeier, K. Mehta, and M Kaufmann Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study Ann. Onc., April 1, 2007; 18(4): 689 - 693. [Abstract] [Full Text] [PDF]

				D. C. Deecher, P. D. Alfinito, L. Leventhal, S. Cosmi, G. H. Johnston, I. Merchenthaler, and R. Winneker Alleviation of Thermoregulatory Dysfunction with the New Serotonin and Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Ovariectomized Rodent Models Endocrinology, March 1, 2007; 148(3): 1376 - 1383. [Abstract] [Full Text] [PDF]

				C. L. Loprinzi, J. W. Kugler, D. L. Barton, A. C. Dueck, L. K. Tschetter, R. A. Nelimark, E. P. Balcueva, K. N. Burger, P. J. Novotny, M. D. Carlson, et al. Phase III Trial of Gabapentin Alone or in Conjunction With an Antidepressant in the Management of Hot Flashes in Women Who Have Inadequate Control With an Antidepressant Alone: NCCTG N03C5 J. Clin. Oncol., January 20, 2007; 25(3): 308 - 312. [Abstract] [Full Text] [PDF]

				D. Grady Management of Menopausal Symptoms N. Engl. J. Med., November 30, 2006; 355(22): 2338 - 2347. [Full Text] [PDF]

				I. Sestak, R. Kealy, R. Edwards, J. Forbes, and J. Cuzick Influence of Hormone Replacement Therapy on Tamoxifen-Induced Vasomotor Symptoms J. Clin. Oncol., August 20, 2006; 24(24): 3991 - 3996. [Abstract] [Full Text] [PDF]

				A. H. Boekhout, J. H. Beijnen, and J. H.M. Schellens Symptoms and treatment in cancer therapy-induced early menopause. Oncologist, June 1, 2006; 11(6): 641 - 654. [Abstract] [Full Text] [PDF]

				H. D. Nelson, K. K. Vesco, E. Haney, R. Fu, A. Nedrow, J. Miller, C. Nicolaidis, M. Walker, and L. Humphrey Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA, May 3, 2006; 295(17): 2057 - 2071. [Abstract] [Full Text] [PDF]

				M. P. Goetz, J. M. Rae, V. J. Suman, S. L. Safgren, M. M. Ames, D. W. Visscher, C. Reynolds, F. J. Couch, W. L. Lingle, D. A. Flockhart, et al. Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes J. Clin. Oncol., December 20, 2005; 23(36): 9312 - 9318. [Abstract] [Full Text] [PDF]

				V. Stearns, R. Slack, N. Greep, R. Henry-Tilman, M. Osborne, C. Bunnell, L. Ullmer, A. Gallagher, J. Cullen, E. Gehan, et al. Paroxetine Is an Effective Treatment for Hot Flashes: Results From a Prospective Randomized Clinical Trial J. Clin. Oncol., October 1, 2005; 23(28): 6919 - 6930. [Abstract] [Full Text] [PDF]

				W. L. Wolfman HRT and antidepressants Can. Med. Assoc. J., August 2, 2005; 173(3): 237 - 237. [Full Text] [PDF]

				Treatment of Menopausal Vasomotor Symptoms Obstet. Gynecol., May 1, 2005; 105(5): 1137 - 1139. [Full Text] [PDF]

				J. A. Schlechte Update in Endocrinology Ann Intern Med, January 18, 2005; 142(2): 126 - 131. [Full Text] [PDF]

				Y. Jin, Z. Desta, V. Stearns, B. Ward, H. Ho, K.-H. Lee, T. Skaar, A. M. Storniolo, L. Li, A. Araba, et al. CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment J Natl Cancer Inst, January 5, 2005; 97(1): 30 - 39. [Abstract] [Full Text] [PDF]

				M. L. Evans, E. Pritts, E. Vittinghoff, K. McClish, K. S. Morgan, and R. B. Jaffe Management of Postmenopausal Hot Flushes With Venlafaxine Hydrochloride: A Randomized, Controlled Trial Obstet. Gynecol., January 1, 2005; 105(1): 161 - 166. [Abstract] [Full Text] [PDF]

				Vasomotor Symptoms Obstet. Gynecol., October 1, 2004; 104(4_suppl): 106S - 117S. [Full Text] [PDF]

				Y. De Sloover Koch and M. E Ernst Selective Serotonin-Reuptake Inhibitors for the Treatment of Hot Flashes Ann. Pharmacother., July 1, 2004; 38(7): 1293 - 1296. [Abstract] [Full Text] [PDF]

				M. P. Goetz and C. L. Loprinzi A Hot Flash on Tamoxifen Metabolism J Natl Cancer Inst, December 3, 2003; 95(23): 1734 - 1735. [Full Text] [PDF]

				V. Stearns, M. D. Johnson, J. M. Rae, A. Morocho, A. Novielli, P. Bhargava, D. F. Hayes, Z. Desta, and D. A. Flockhart Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine J Natl Cancer Inst, December 3, 2003; 95(23): 1758 - 1764. [Abstract] [Full Text] [PDF]

				C. E Schober and N. T Ansani Venlafaxine Hydrochloride for the Treatment of Hot Flashes Ann. Pharmacother., November 1, 2003; 37(11): 1703 - 1707. [Abstract] [Full Text] [PDF]

				C. A. Thompson, T. D. Shanafelt, and C. L. Loprinzi Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation Oncologist, October 1, 2003; 8(5): 474 - 487. [Abstract] [Full Text] [PDF]

				V. Stearns, K. L. Beebe, M. Iyengar, and E. Dube Paroxetine Controlled Release in the Treatment of Menopausal Hot Flashes: A Randomized Controlled Trial JAMA, June 4, 2003; 289(21): 2827 - 2834. [Abstract] [Full Text] [PDF]

				C. E. Piersen Phytoestrogens in Botanical Dietary Supplements: Implications for Cancer Integr Cancer Ther, June 1, 2003; 2(2): 120 - 138. [Abstract] [PDF]

				S. Y. El-Ibiary and K. C. Lee Novel Uses of Selective Serotonin Reuptake Inhibitors in Women Journal of Pharmacy Practice, June 1, 2003; 16(3): 191 - 199. [Abstract] [PDF]

				H. Kattlove and R. J. Winn Ongoing Care of Patients After Primary Treatment for Their Cancer CA Cancer J Clin, May 1, 2003; 53(3): 172 - 196. [Abstract] [Full Text] [PDF]

				J. Rosack Antidepressants Reduce Hot Flashes, May Be Estrogen Alternative Psychiatr News, April 5, 2002; 37(7): 29 - 29. [Full Text]

				V. Stearns and D. F. Hayes Cooling Off Hot Flashes J. Clin. Oncol., March 15, 2002; 20(6): 1436 - 1438. [Full Text] [PDF]